• Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate TPST-2003
  • Results support clinical benefit of parallel-structure dual-targeting CAR architecture in patients with relapsed/refractory multiple myeloma
  • Data further support potential of TPST-2003 to improve outcomes for patients with extramedullary disease

     

BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest") will present its most recent clinical data from its lead dual-targeting chimeric antigen receptor T-cell ("CAR-T") therapy product candidate, TPST-2003, at the International Society for Cell & Gene Therapy ("ISCT") Scientific Annual Meeting in Dublin, May 6-9, 2026. Updates will include the latest data from the ongoing REDEEM-1 Phase 1/2a trial evaluating TPST-2003, as well as progress in Tempest's other dual-targeting CAR-T pipeline programs.

Earlier this year, Tempest announced positive interim data from REDEEM-1, including a 100% complete response rate among all six efficacy then-evaluable patients according to the International Myeloma Working Group (IMWG) uniform response criteria, as well as a favorable safety profile.